Cancer vaccine plus checkpoint inhibitor extends survival

Country

Netherlands

New data on a prospective vaccine for human papillomavirus type 16 (HPV-16)-induced cancers has demonstrated efficacy in combination with the checkpoint inhibitor nivolumab (Opdivo), ISA Pharmaceuticals BV announced on 1 March. The vaccine, ISA101b, consists of synthetic long peptides that are specific to the E6 and E7 proteins on the virus. These proteins play an important role in HPV-induced cancers.